HUE056127T2 - A rák kezelésének módszerei 3-(4-((4-(morfolino-metil)-benzil)-oxi) -1-oxi-izo-dolin-2-il) - piperidin-2,6-dion alkalmazásával - Google Patents

A rák kezelésének módszerei 3-(4-((4-(morfolino-metil)-benzil)-oxi) -1-oxi-izo-dolin-2-il) - piperidin-2,6-dion alkalmazásával

Info

Publication number
HUE056127T2
HUE056127T2 HUE13751007A HUE13751007A HUE056127T2 HU E056127 T2 HUE056127 T2 HU E056127T2 HU E13751007 A HUE13751007 A HU E13751007A HU E13751007 A HUE13751007 A HU E13751007A HU E056127 T2 HUE056127 T2 HU E056127T2
Authority
HU
Hungary
Prior art keywords
oxoisoindolin
morpholinomethyl
dione
piperidine
oxy
Prior art date
Application number
HUE13751007A
Other languages
English (en)
Inventor
Peter Schafer
Anita Gandhi
Original Assignee
Celgene Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Corp filed Critical Celgene Corp
Publication of HUE056127T2 publication Critical patent/HUE056127T2/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Hydrogenated Pyridines (AREA)
HUE13751007A 2012-08-09 2013-08-08 A rák kezelésének módszerei 3-(4-((4-(morfolino-metil)-benzil)-oxi) -1-oxi-izo-dolin-2-il) - piperidin-2,6-dion alkalmazásával HUE056127T2 (hu)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261681447P 2012-08-09 2012-08-09
US201261722727P 2012-11-05 2012-11-05

Publications (1)

Publication Number Publication Date
HUE056127T2 true HUE056127T2 (hu) 2022-01-28

Family

ID=49004013

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE13751007A HUE056127T2 (hu) 2012-08-09 2013-08-08 A rák kezelésének módszerei 3-(4-((4-(morfolino-metil)-benzil)-oxi) -1-oxi-izo-dolin-2-il) - piperidin-2,6-dion alkalmazásával

Country Status (31)

Country Link
US (3) US20140045843A1 (hu)
EP (2) EP3949968A1 (hu)
JP (2) JP6347782B2 (hu)
KR (3) KR102146848B1 (hu)
CN (4) CN114366746A (hu)
AU (1) AU2013299627C1 (hu)
BR (1) BR112015002285B1 (hu)
CA (1) CA2881116C (hu)
CY (1) CY1124622T1 (hu)
DK (1) DK2882442T3 (hu)
EA (1) EA029485B1 (hu)
ES (1) ES2881220T3 (hu)
HK (1) HK1211489A1 (hu)
HR (1) HRP20211243T1 (hu)
HU (1) HUE056127T2 (hu)
IL (3) IL288506B2 (hu)
IN (1) IN2015DN00886A (hu)
LT (1) LT2882442T (hu)
MX (1) MX367869B (hu)
NI (1) NI201500012A (hu)
NZ (1) NZ628078A (hu)
PH (1) PH12015500212A1 (hu)
PL (1) PL2882442T3 (hu)
PT (1) PT2882442T (hu)
RS (1) RS62201B1 (hu)
SG (3) SG10202108516PA (hu)
SI (1) SI2882442T1 (hu)
TW (2) TWI723266B (hu)
UA (1) UA116544C2 (hu)
WO (1) WO2014025960A1 (hu)
ZA (1) ZA201500564B (hu)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5645816B2 (ja) 2009-05-25 2014-12-24 国立大学法人東京工業大学 中枢神経細胞の増殖及び分化に係る中核因子を含む医薬組成物
US8491927B2 (en) * 2009-12-02 2013-07-23 Nimble Epitech, Llc Pharmaceutical composition containing a hypomethylating agent and a histone deacetylase inhibitor
ME03441B (me) 2010-02-11 2020-01-20 Celgene Corp DERIVATI ARILMETOKSI IZOINDOLINA l KOMPOZICIJE KOJE IH OBUHVATAJU l POSTUPCI NJIHOVE PRIMENE
DK2691384T3 (en) 2011-03-28 2017-01-16 Mei Pharma Inc (ALPHA-SUBSTITUTED ARALKYLAMINO AND HETEROARYLALKYLAMINO) PYRIMIDINYL AND 1,3,5-TRIAZINYL BENZIMIDAZOLES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEMSELVES AND THEIR SUBSTANCES CONCERNING THE USE OF THE USE
EP3904875A1 (en) 2012-06-29 2021-11-03 Celgene Corporation Methods for determining drug efficacy using ikzf3 (aiolos)
US9587281B2 (en) 2012-08-14 2017-03-07 Celgene Corporation Cereblon isoforms and their use as biomarkers for therapeutic treatment
JP6306592B2 (ja) 2012-09-10 2018-04-04 セルジーン コーポレイション 局所進行乳癌を治療するための方法
US9695145B2 (en) 2013-01-22 2017-07-04 Celgene Corporation Processes for the preparation of isotopologues of 3-(4-((4- morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione and pharmaceutically acceptable salts thereof
MX2016007239A (es) * 2013-12-06 2017-01-05 Celgene Corp Metodos para determinar la eficacia del farmaco para el tratamiento de linfoma difuso de celulas b grandes, mieloma multiple, y canceres mieloides.
US10092555B2 (en) 2014-06-27 2018-10-09 Celgene Corporation Compositions and methods for inducing conformational changes in cereblon and other E3 ubiquitin ligases
WO2016057503A1 (en) * 2014-10-07 2016-04-14 Celgene Corporation Use of biomarkers for predicting clinical sensitivity to cancer treatment
WO2017053555A1 (en) * 2015-09-25 2017-03-30 Celgene Corporation Methods for treating diffuse large b-cell lymphoma and the use of biomarkers as a predictor of responsiveness to drugs
US10830762B2 (en) 2015-12-28 2020-11-10 Celgene Corporation Compositions and methods for inducing conformational changes in cereblon and other E3 ubiquitin ligases
KR102002581B1 (ko) * 2016-10-04 2019-07-22 주식회사 종근당 혈액암 치료를 위한 hdac 저해제 및 프로테아좀 억제제 또는 면역조절성 약물을 포함하는 약학적 조합물
US20180238886A1 (en) * 2017-01-31 2018-08-23 Celgene Corporation Methods for treating hematological cancer and the use of biomarkers as a predictor for responsiveness to treatment compounds
AU2018269982A1 (en) * 2017-05-16 2020-01-02 Biomed Valley Discoveries, Inc. Compositions and methods for treating cancer with atypical BRAF mutations
CA3063976A1 (en) 2017-05-23 2018-11-29 Mei Pharma, Inc. Combination therapy
MX2019015886A (es) * 2017-06-30 2020-09-10 Celgene Corp Composiciones y metodos de uso de 2-(4-clorofenil)-n-((2-(2,6-diox opiperidin-3-il)-1-0xoisoindolin-5-il)metil)-2,2-difluoroacetamid a.
BR112020000442A2 (pt) * 2017-07-10 2020-07-21 Celgene Corporation compostos antiproliferativos e métodos de uso dos mesmos
MA49921A (fr) 2017-08-14 2021-05-12 Mei Pharma Inc Polythérapie
US11358948B2 (en) 2017-09-22 2022-06-14 Kymera Therapeutics, Inc. CRBN ligands and uses thereof
US11709164B2 (en) 2017-10-26 2023-07-25 National University Of Singapore Approach for universal monitoring of minimal residual disease in acute myeloid leukemia
EP3737675A4 (en) 2018-01-12 2022-01-05 Kymera Therapeutics, Inc. CRBN LIGANDS AND THEIR USES
WO2020010177A1 (en) 2018-07-06 2020-01-09 Kymera Therapeutics, Inc. Tricyclic crbn ligands and uses thereof
US20210196725A1 (en) * 2018-08-14 2021-07-01 Mei Pharma, Inc. Treatment of relapsed follicular lymphoma
US11319330B2 (en) 2018-09-07 2022-05-03 Medshine Discovery Inc. Tricyclic furan-substituted piperidinedione compound
WO2020072334A1 (en) 2018-10-01 2020-04-09 Celgene Corporation Combination therapy for the treatment of cancer
JP2022516401A (ja) 2018-11-30 2022-02-28 カイメラ セラピューティクス， インコーポレイテッド Ｉｒａｋ分解剤およびそれらの使用
AR119715A1 (es) * 2019-04-12 2022-01-05 Celgene Corp Métodos para tratar linfoma no hodgkin con el uso de 2-(2,6-dioxopiperidin-3-il)-4-((2-fluoro-4-((3-morfolinoazetidin-1-il)metil)bencil)amino)isoindolin-1,3-diona
EA039874B1 (ru) * 2019-06-06 2022-03-22 Общество С Ограниченной Ответственностью "Технология Лекарств" Композиция помалидомида для лечения заболеваний, ассоциированных с фактором некроза опухоли (фно)
JP2022554353A (ja) 2019-11-07 2022-12-28 ジュノー セラピューティクス インコーポレイテッド Ｔ細胞療法と（ｓ）－３－［４－（４－モルホリン－４－イルメチル－ベンジルオキシ）－１－オキソ－１，３－ジヒドロ－イソインドール－２－イル］－ピペリジン－２，６－ジオンとの併用
CA3159978A1 (en) 2019-12-02 2021-06-10 Celgene Corporation Therapy for the treatment of cancer
TW202136242A (zh) 2019-12-23 2021-10-01 美商凱麥拉醫療公司 Smarca降解劑及其用途
CA3171258A1 (en) 2020-03-19 2021-09-23 Nan JI Mdm2 degraders and uses thereof
TW202210483A (zh) 2020-06-03 2022-03-16 美商凱麥拉醫療公司 Irak降解劑之結晶型
BR112022026090A2 (pt) * 2020-06-25 2023-01-17 Celgene Corp Métodos para tratar câncer com terapias de combinação
WO2024015618A2 (en) * 2022-07-15 2024-01-18 St. Jude Children's Research Hospital, Inc. Substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione/2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione analogs as modulators of cereblon protein
WO2024064646A1 (en) 2022-09-20 2024-03-28 Celgene Corporation Salts and solid forms of (s)- or racemic 3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione and methods of using the same

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
US5391485A (en) 1985-08-06 1995-02-21 Immunex Corporation DNAs encoding analog GM-CSF molecules displaying resistance to proteases which cleave at adjacent dibasic residues
US4810643A (en) 1985-08-23 1989-03-07 Kirin- Amgen Inc. Production of pluripotent granulocyte colony-stimulating factor
JPS63500636A (ja) 1985-08-23 1988-03-10 麒麟麦酒株式会社 多分化能性顆粒球コロニー刺激因子をコードするｄｎａ
US5073543A (en) 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
IT1229203B (it) 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5733566A (en) 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
US5360352A (en) 1992-12-24 1994-11-01 The Whitaker Corporation Wire retainer for current mode coupler
US5591767A (en) 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
IT1270594B (it) 1994-07-07 1997-05-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
CA2418835A1 (en) 2000-10-16 2002-04-25 Phylos, Inc. Protein scaffolds for antibody mimics and other binding proteins
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
AU2002256371B2 (en) 2001-04-26 2008-01-10 Amgen Mountain View Inc. Combinatorial libraries of monomer domains
US7498171B2 (en) 2002-04-12 2009-03-03 Anthrogenesis Corporation Modulation of stem and progenitor cell differentiation, assays, and uses thereof
US7968569B2 (en) 2002-05-17 2011-06-28 Celgene Corporation Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione
US7393862B2 (en) 2002-05-17 2008-07-01 Celgene Corporation Method using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for treatment of certain leukemias
US20060234299A1 (en) 2004-11-16 2006-10-19 Avidia Research Institute Protein scaffolds and uses thereof
US20080051379A1 (en) 2004-12-01 2008-02-28 Trustees Of Boston University Compositions and Methods for the Treatment of Peripheral B-Cell Neoplasms
KR20170093996A (ko) * 2007-03-20 2017-08-16 셀진 코포레이션 4'-ｏ-치환된 아이소인돌린 유도체 및 이를 포함하는 조성물 및 이의 사용 방법
JP5645816B2 (ja) 2009-05-25 2014-12-24 国立大学法人東京工業大学 中枢神経細胞の増殖及び分化に係る中核因子を含む医薬組成物
ME03441B (me) * 2010-02-11 2020-01-20 Celgene Corp DERIVATI ARILMETOKSI IZOINDOLINA l KOMPOZICIJE KOJE IH OBUHVATAJU l POSTUPCI NJIHOVE PRIMENE
MX2012010367A (es) * 2010-03-12 2012-11-23 Celgene Corp Metodos para el tratamiento de linfomas no hodgkin que usan lenalidomida y biomarcadores de genes y proteinas como un predictor.
CN103561743A (zh) * 2011-03-11 2014-02-05 细胞基因公司 利用3-(5-氨基-2-甲基-4-氧-4h-喹唑啉-3-基)-哌啶-2,6-二酮治疗癌症的方法

Also Published As

Publication number Publication date
NI201500012A (es) 2019-05-10
KR102266510B1 (ko) 2021-06-16
TWI723266B (zh) 2021-04-01
BR112015002285B1 (pt) 2022-05-10
EA029485B1 (ru) 2018-04-30
EP3949968A1 (en) 2022-02-09
BR112015002285A2 (pt) 2017-07-04
PT2882442T (pt) 2021-08-17
IL288506B1 (en) 2023-05-01
AU2013299627A1 (en) 2015-02-05
EA201590345A1 (ru) 2015-06-30
PL2882442T3 (pl) 2021-12-13
US20140045843A1 (en) 2014-02-13
HRP20211243T1 (hr) 2021-11-12
IL276319B (en) 2022-01-01
KR20200098730A (ko) 2020-08-20
AU2013299627B2 (en) 2018-02-15
IL288506B2 (en) 2023-09-01
PH12015500212A1 (en) 2015-03-30
SI2882442T1 (sl) 2021-11-30
CA2881116A1 (en) 2014-02-13
US20190388429A1 (en) 2019-12-26
DK2882442T3 (da) 2021-08-16
SG11201500998QA (en) 2015-04-29
WO2014025960A1 (en) 2014-02-13
SG10201701057SA (en) 2017-03-30
SG10202108516PA (en) 2021-09-29
HK1211489A1 (en) 2016-05-27
TW201828944A (zh) 2018-08-16
CN114344307A (zh) 2022-04-15
JP2018100276A (ja) 2018-06-28
KR102146848B1 (ko) 2020-08-21
LT2882442T (lt) 2021-09-27
CN108245518A (zh) 2018-07-06
CY1124622T1 (el) 2022-07-22
CN108245518B (zh) 2021-08-31
EP2882442B1 (en) 2021-06-09
IL288506A (en) 2022-01-01
CN104837491A (zh) 2015-08-12
IL237013B (en) 2020-08-31
KR102414005B1 (ko) 2022-06-27
ZA201500564B (en) 2016-06-29
IL276319A (en) 2020-09-30
JP6347782B2 (ja) 2018-06-27
CA2881116C (en) 2021-07-20
IL237013A0 (en) 2015-03-31
MX367869B (es) 2019-09-10
KR20150039850A (ko) 2015-04-13
NZ628078A (en) 2017-01-27
RS62201B1 (sr) 2021-08-31
CN114366746A (zh) 2022-04-19
EP2882442A1 (en) 2015-06-17
AU2013299627C1 (en) 2018-05-31
KR20210073617A (ko) 2021-06-18
IN2015DN00886A (hu) 2015-06-12
US20160256468A1 (en) 2016-09-08
ES2881220T3 (es) 2021-11-29
MX2015001775A (es) 2015-05-12
TWI653977B (zh) 2019-03-21
JP2015524478A (ja) 2015-08-24
TW201434466A (zh) 2014-09-16
UA116544C2 (uk) 2018-04-10

Similar Documents

Publication Publication Date Title
IL288506A (en) Methods for treating cancer using 3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoisoindolin-2-yl)piperidine-2,6-dione
HK1191858A1 (zh) 利用 -氨基- -甲基- -氧- -喹唑啉- -基 -呱啶- -二酮治療癌症的方法
HRP20190398T1 (hr) Čvrsti oblik (s)-3-(4-((4-morfolinometil)benzil)oksi)-1-oksoizoindolin-2-il)piperidin-2,6-dion hidroklorida
IL244494B (en) Formulations of 3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindoline-2-yl)piperidine-6,2-dione
IL236925A0 (en) Processes for the preparation of (s)-3-4-((4-morpholinomethyl)benzyl)oxy)-1-oxoisoindoline-2-yl)piperidine-6,2-dione and acceptable pharmaceutical forms thereof